Is Rybelsus Safe in the First Trimester? What Every Woman Needs to Know

Can You Take Rybelsus in the First Trimester?

No. Rybelsus is contraindicated in the first trimester and at every other point in pregnancy. The FDA prescribing information for Rybelsus states directly that the drug should be discontinued when pregnancy is detected, and that adequate human data on pregnancy outcomes are not available to establish whether there is a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

The first trimester is the period of organogenesis, when a developing embryo's heart, brain, spine, and limbs form. Exposing that process to an incompletely characterized agent carries real uncertainty. With Rybelsus, the uncertainty leans toward harm.

What the Animal Data Show

Animal reproductive studies are not perfectly predictive for humans, but they are the primary data we have. In studies conducted in rats and rabbits at doses that produced exposures comparable to the maximum recommended human dose, semaglutide caused embryo-fetal mortality, structural abnormalities, and growth restriction. Skeletal malformations were observed in both species.

These findings align with what has been seen across the GLP-1 receptor agonist class. A 2024 analysis published in JAMA examining GLP-1 receptor agonist use in early pregnancy found an association with increased risk of major birth defects compared with no treatment, though the absolute risk increase was modest and confounding by underlying diabetes could not be fully excluded. The study does not exonerate first-trimester exposure.

Why "I Didn't Know I Was Pregnant Yet" Is a Common Situation

Many women take Rybelsus for type 2 diabetes or off-label for weight loss and become pregnant without planning to. Missed periods are common in women with PCOS or obesity-related cycle irregularities, two conditions that often prompt GLP-1 use in the first place. This means the window between conception and recognition of pregnancy can stretch to six or more weeks, covering nearly half the first trimester.

If you took Rybelsus before knowing you were pregnant, that is a very common scenario. Stop the medication now, call your OB or endocrinologist today, and contact the Novo Nordisk pregnancy exposure registry at 1-800-727-6500. Prospective registry data are the fastest way to build human safety evidence, and your enrollment genuinely helps other women.

Why Rybelsus Is Prescribed to Women in Reproductive Years

Understanding the context matters. Rybelsus received FDA approval in September 2019 as the first oral GLP-1 receptor agonist for adults with type 2 diabetes. Off-label, it is used for weight management, and that use has expanded rapidly.

The Conditions That Overlap With Reproductive Age

Several conditions disproportionately affecting women of reproductive age also respond to GLP-1 receptor agonists.

Type 2 diabetes. The prevalence of T2D in women aged 20 to 44 has risen significantly. Women with T2D face higher cardiovascular risk relative to their male counterparts, and GLP-1 agents address glycemia, weight, and cardiac risk simultaneously, making them attractive to clinicians.

PCOS. Polycystic ovary syndrome affects 8 to 13 percent of women of reproductive age and is associated with insulin resistance, obesity, and cycle irregularity. Semaglutide has been studied in PCOS, with a 2023 randomized controlled trial in Fertility and Sterility reporting reductions in BMI, androgen levels, and menstrual irregularity in women with PCOS. Improved ovulation is a direct consequence, which paradoxically raises pregnancy risk in women who were previously anovulatory and not using contraception.

Obesity. Roughly 40 percent of US women are living with obesity, a condition now treated more aggressively with pharmacotherapy. Women who start Rybelsus or injectable semaglutide for weight loss may not receive explicit counseling about the contraception requirement.

The Contraception Gap

ACOG Committee Opinion 990 recommends that women of reproductive age who are prescribed GLP-1 receptor agonists for obesity or diabetes be counseled about the need for effective contraception. The concern goes beyond teratogenicity: weight loss itself can restore ovulation in women with PCOS or obesity-related anovulation, creating a pregnancy risk that did not exist before treatment began.

Oral contraceptives taken simultaneously with Rybelsus present a practical issue. The SNAC absorption-enhancing mechanism of oral semaglutide briefly raises gastric pH, and because the tablet must be taken on an empty stomach with plain water only, spacing from other medications matters. Your prescriber should review your full medication list including your contraceptive method.

Sex-Specific Pharmacokinetics: Why Dosing and Risk Are Not the Same as in Men

Clinical trials for Rybelsus enrolled both sexes, but the pharmacokinetic data broken out by sex show that women generally have higher semaglutide plasma exposures than men at equivalent body weight-adjusted doses, a pattern seen across the GLP-1 class. Higher exposure in women may mean that the animal-to-human dose comparison understates the human effective dose in female patients, which is relevant to interpreting the animal reproductive toxicology data.

Women also experience GLP-1 side effects, nausea, vomiting, and gastric emptying delay, at higher rates than men. In early pregnancy, when nausea gravidarum is already present, the additive burden from continued Rybelsus use could worsen nutritional intake and hydration at precisely the period when fetal neural tube formation depends on folate availability.

Pregnancy and Lactation: The Complete Safety Picture

This section is required reading if you are pregnant, trying to conceive, or breastfeeding while on Rybelsus for any indication.

Pregnancy: What the Evidence Actually Says

The evidence base for Rybelsus in human pregnancy is thin. Honest clinical communication requires stating that clearly.

The FDA Rybelsus label summarizes the situation as follows: there are no adequate and well-controlled studies in pregnant women. The animal data showing fetal harm are the basis for the contraindication, not confirmed human teratogenicity, because the human data simply do not exist at the scale needed to draw firm conclusions.

A 2024 cohort study in the New England Journal of Medicine examined pregnancy outcomes in women who used GLP-1 receptor agonists (primarily injectable semaglutide and liraglutide) in the first trimester and found no statistically significant increase in major congenital malformations compared with insulin users. The absolute event rate was low, the study was underpowered for rare outcomes, and oral semaglutide specifically was not disaggregated. This is reassuring but not exonerating. The study authors themselves caution against changing prescribing guidance based on its findings alone.

The honest summary: we do not have enough human data to call Rybelsus safe in pregnancy, and the animal data give clear reason for concern. The contraindication stands.

How Long Should You Stop Rybelsus Before Trying to Conceive?

The plasma half-life of semaglutide is approximately one week. Based on standard pharmacokinetic principles (five half-lives to near-complete elimination), the drug clears the body in roughly five weeks. The FDA label recommends discontinuing Rybelsus at least two months before a planned pregnancy to allow full clearance and to create a buffer. Two months is the standard clinical recommendation your provider will give you.

During that washout period, your glycemia or weight management plan needs to be actively reassigned. For women with T2D, ACOG Practice Bulletin 201 designates insulin as the preferred pharmacological agent for glycemic control during pregnancy because of its established safety record and inability to cross the placenta in significant amounts.

Breastfeeding and Rybelsus

The safety data for Rybelsus during breastfeeding are similarly absent. The NIH LactMed database entry for semaglutide states that no published information is available on the use of semaglutide during breastfeeding, and because of concerns about potential effects on the nursing infant's growth and development, an alternative drug should be considered during the postpartum period.

Semaglutide is a large peptide molecule (approximately 4,113 daltons), and high-molecular-weight compounds typically transfer poorly into breast milk and are poorly absorbed from the infant gut. That theoretical reassurance does not substitute for actual safety data. The recommendation is to avoid Rybelsus while breastfeeding.

If you have T2D and are postpartum and breastfeeding, insulin remains the standard of care. Your endocrinologist can help you transition to a postpartum insulin regimen that accounts for the increased insulin sensitivity many women experience while nursing.

Postpartum and the Return to Rybelsus

If you were on Rybelsus before pregnancy and want to resume it after delivery, the timing depends on whether you are breastfeeding. Women who are not breastfeeding may discuss resumption with their provider once the immediate postpartum period has passed and their medication plan is reassessed, typically at the six-week postpartum visit. Women who are breastfeeding should wait until they have fully weaned.

Managing Your Conditions During Pregnancy: Practical Alternatives

Stopping Rybelsus does not mean stopping care for the underlying condition it was treating. Each condition requires its own pregnancy-safe approach.

If You Were Taking Rybelsus for Type 2 Diabetes

Insulin is the gold standard. ACOG Practice Bulletin 201 recommends basal-bolus insulin regimens for most pregnant women with pregestational T2D. Metformin is sometimes used adjunctively, though debate exists about its placental transfer and long-term effects in offspring. Your maternal-fetal medicine specialist and endocrinologist should co-manage your glycemia from preconception onward.

Target A1C before conception is below 6.5 percent if achievable without significant hypoglycemia, per ACOG guidance. The fetal cardiac and neural tube structures form between weeks four and eight of gestation, often before a woman knows she is pregnant, which is why preconception glycemic optimization is not optional.

If You Were Taking Rybelsus Off-Label for Weight Loss

Weight management during pregnancy follows different rules. Gestational weight gain recommendations from the Institute of Medicine, still referenced by ACOG, are based on pre-pregnancy BMI. Women with obesity (BMI ≥30) are advised to gain 11 to 20 pounds across the full pregnancy, which is substantially less than women with normal BMI. The focus shifts entirely to nutrition quality, appropriate caloric intake, and safe physical activity. No pharmacological weight-loss agent is approved or considered safe in pregnancy.

If You Were Taking Rybelsus for PCOS

PCOS management in pregnancy centers on monitoring for gestational diabetes (women with PCOS are at higher risk), managing blood pressure, and in some cases continuing low-dose aspirin for preeclampsia prevention if risk factors are present. The ASRM practice committee does not endorse GLP-1 agents during pregnancy for PCOS management.

Who Should Not Take Rybelsus (and Who Might Be a Candidate Before Trying to Conceive)

This life-stage framework helps you and your provider think through Rybelsus in the context of your reproductive goals.

| Life Stage | Rybelsus Use | Key Consideration | |---|---|---| | Reproductive age, not planning pregnancy | May be appropriate with reliable contraception | Counsel on ovulation restoration with weight loss | | Actively trying to conceive | Stop at least 2 months before attempting conception | Transition T2D management to insulin preconceptionally | | Pregnant (any trimester) | Contraindicated. Stop immediately. | Call provider today; enroll in exposure registry | | Postpartum, not breastfeeding | Discuss resumption at 6-week visit | Reassess indication and metabolic status | | Postpartum, breastfeeding | Not recommended | Use insulin for T2D; wait until fully weaned | | Perimenopause or postmenopause | Pregnancy risk near zero; no reproductive contraindication | Standard cardiovascular and metabolic precautions apply |

Women in perimenopause deserve a specific note. Irregular cycles in perimenopause can make it difficult to recognize a surprise pregnancy. Perimenopause does not equal infertility. ACOG recommends that women in perimenopause continue contraception until 12 months after the final menstrual period if they wish to avoid pregnancy. This is relevant for women who are also on Rybelsus during that transition.

What Clinicians Are Saying: Evidence Gaps and Honest Uncertainty

The women's-health medical community is watching the GLP-1 and pregnancy data space closely. The evidence gap is real and acknowledged. As stated in the 2024 NEJM cohort study on GLP-1 use in early pregnancy, "these findings should not be used to change current guidelines, which recommend discontinuing GLP-1 receptor agonists before conception or as soon as pregnancy is recognized."

Women have historically been under-represented in drug trials, and pregnant women even more so. The GLP-1 receptor agonist class exploded in clinical use before reproductive safety data could catch up. The ACOG Committee on Clinical Consensus on Obstetrics does not include any GLP-1 agent in its gestational diabetes algorithm, precisely because that data gap exists.

What this means for you practically: your provider's recommendation to stop Rybelsus before or upon discovering pregnancy is not overcaution. It reflects the correct application of the available evidence.

First Steps If You Are Pregnant and Have Been Taking Rybelsus

Stop Rybelsus today. A single dose missed will not resolve the question of prior exposure, but continuing to take it adds to it.

Call your OB, maternal-fetal medicine specialist, or endocrinologist within 24 hours. Tell them the dose you were on (7 mg, 14 mg, or the maximum 14 mg dose), when you started, and your best estimate of gestational age.

Enroll in the Novo Nordisk Ozempic/Rybelsus/Wegovy pregnancy exposure registry by calling 1-800-727-6500. Enrollment is voluntary but gives you access to follow-up data on outcomes and contributes to the evidence base for every woman who faces this situation after you.

Request a fetal anatomy ultrasound at the appropriate gestational age (typically 18 to 20 weeks) to assess for structural anomalies. This is standard of care for any pregnancy with a potential teratogenic exposure, and your provider should arrange it as part of routine prenatal care in this context.

Your A1C should be checked if you were using Rybelsus for T2D, and insulin should be started or optimized without delay. A1C above 10 percent at conception is associated with a major malformation risk of up to 20 to 25 percent, so glycemic control is the highest-priority clinical action.